Results 61 to 70 of about 12,992 (201)

Transplantation in pediatric aHUS within the era of eculizumab therapy

, 2021
aHUS is caused by the over-activation and dysregulation of the alternative complement pathway. Data regarding outcomes of pediatric aHUS patients after kidney transplantation are still very scarce.
Fatih Ozaltin, TOPALOĞLU, REZAN, Nur Canpolat, Baskin, Esra, Yuruk Yildirim, Zeynep, Kasap Demir, Belde, ÖZÇAKAR, ZEYNEP BİRSİN, Demircioglu Kilic, Beltinge, Parmaksiz, Gonul, Zeynep Yuruk Yildirim, Oğuz Söylemezoğlu, Zeynep Birsin Özçakar, Elif Çomak, Bora Gülhan, YÜKSEL, SELÇUK, ÇOMAK, ELİF, Gönül Parmaksız, Selçuk Yüksel, ÖZALTIN, FATİH, Beltinge Demircioğlu Kılıç, GÜLHAN, BORA, Canpolat, Nur, Belde Kasap Demir, Soylemezoglu, Oguz, Esra Baskın, Rezan Topaloğlu   +25 more
core   +2 more sources

Successful Pregnancies During Ongoing Eculizumab Therapy in Two Patients With Complement-Mediated Thrombotic Microangiopathy

Kidney Medicine, 2020
In patients with pregnancy-associated complement gene variant–mediated thrombotic microangiopathy (cTMA), terminal complement blockade is used for treatment of cTMA flares during pregnancy or following delivery.
Natalja Haninger-Vacariu, Christof Aigner, Renate Kain, Zoltán Prohászka, Martina Gaggl, Georg A. Böhmig, Leah Charlotte Piggott, Raute Sunder-Plassmann, Gere Sunder-Plassmann, Alice Schmidt   +9 more
doaj   +1 more source

Operationalization of the African Medicines Agency: Retrospective evaluation of the continental centralized pilot procedure timelines to recommendation and national registrations

British Journal of Clinical Pharmacology, EarlyView.
Aims Regulatory inconsistency across Africa causes duplicative assessments, prolonged approvals, and delayed medical access. To inform the African Medicines Agency (AMA), the African Medicines Regulatory Harmonisation (AMRH) piloted Africa's first continental scientific evaluation of human medicinal products.
Alex Juma Ismail, Lerato Moeti, Delese Mimi Darko, Stuart Walker, Sam Salek   +4 more
wiley   +1 more source

Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor, Takanobu Nadai, Kei Irie, Wen Rui Tan, Sanjana Parikh, Anhar Hosawi, Matthijs W. van Hoogdalem, Ronaldo Morales Junior, Sonya Tang Girdwood, Abbie D. Leino, Kana Mizuno, Alexander A. Vinks, Tomoyuki Mizuno   +12 more
wiley   +1 more source

Eculizumab in kidney diseases [PDF]

The C5 inhibitor monoclonal antibody, eculizumab, has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); however, the efficacy and safety of this drug in treating other complement ...
Fatemeh Pour-Reza-Gholi, Sara Assadiasl
core   +2 more sources

Thrombotic microangiopathy after kidney transplantation successfully treated with eculizumab: A case report

Transplantation Reports, 2018
Background: Transplantation-associated thrombotic microangiopathy (TA-TMA) is relatively rare and may cause graft failure. Atypical hemolytic uremic syndrome (aHUS) is caused by dysregulation of the alternative complement pathway, resulting in TMA ...
Tomoko Kawanishi, Jumpei Hasegawa, Momoko Kono, Ayumi Ishiwatari, Toshie Ogawa, Yasutomo Abe, Mariko Endo, Hidetoshi Ishigooka, Masayoshi Okumi, Kazunari Tanabe, Sachiko Wakai, Hiroki Shirakawa   +11 more
doaj   +1 more source

Fatigue in Myasthenia Gravis: Recent Advances and Emerging Concepts

Muscle &Nerve, EarlyView.
ABSTRACT Fatigue is a common, often disabling symptom in myasthenia gravis (MG), distinct from muscle fatigability, and strongly associated with reduced quality of life. This narrative review examines current evidence on fatigue in MG, its patient impact, and future research directions. Earlier studies, mostly small and heterogeneous, reported a highly
Yvonne J. M. Campman, Martijn R. Tannemaat, Annabel M. Ruiter, Sarah Hoffmann   +3 more
wiley   +1 more source

Clinical Characteristics and Treatment Management of Seronegative Myasthenia Gravis: A Systematic Review of the Literature

Muscle &Nerve, EarlyView.
ABSTRACT Seronegative myasthenia gravis (SNMG) is characterized by the absence of detectable autoantibodies against known MG targets, despite clinical and electrophysiological evidence of a postsynaptic neuromuscular junction disorder. The aim of this systematic review was to better define clinical features, diagnostic clues and treatment outcome of ...
Massimiliano Ugo Verza, Mattia Schiavolin, Francesca Beretta, Sara Cornacchini, Antonio Lotti, Gregorio Spagni, Valentina Damato   +6 more
wiley   +1 more source

Optimization of the Cell‐Based Assay Methodology to Study Degradation of Acetylcholine Receptors (Antigenic Modulation) by Antibodies From Myasthenia Gravis Patients

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Degradation of cell‐surface acetylcholine receptors (AChRs) by antigenic modulation is a key pathogenic mechanism of myasthenia gravis (MG) autoantibodies, yet standard assays primarily detect antibody binding rather than functional effects.
Peng Du, Marina Mané‐Damas, Fien M. Verhamme, Mahan Moshir, Peter Ulrichts, Barbie Machiels, Mario Losen, Pilar Martinez‐Martinez   +7 more
wiley   +1 more source

Eculizumab for Shiga‐toxin‐induced hemolytic uremic syndrome in adults with neurological involvement

eJHaem
The role of eculizumab in treating Shiga‐toxin‐producing Escherichia coli (STEC) hemolytic uremic syndrome (HUS) patients with neurological involvement remains unclear.
Benjamin J. Lee, Zhaohui Arter, Jean Doh, Shawn P. Griffin, Pongthep Vittayawacharin, Steven Atallah, Kevin R. Shieh, Minh‐Ha Tran, Sonata Jodele, Piyanuch Kongtim, Stefan O. Ciurea   +10 more
doaj   +1 more source